EasyDiagnosis Biomedicine Co., Ltd. is a leading publicly listed biotechnology company headquartered in Wuhan, China, specializing in the research, development, manufacturing, and marketing of In-Vitro Diagnostic (IVD) products. Since its establishment in 2008, the company has been dedicated to its mission of “providing better health for everyone” by delivering accurate, real-time, and smart diagnostic solutions that empower healthcare systems globally.

EasyDiagnosis operates across four major business segments—Blood Gas Analysis, Immuno Diagnostics, Molecular Diagnostics, and Coagulation Analysis—offering comprehensive testing solutions for clinical laboratories and point-of-care applications. Its POCT (Point-of-Care Testing) systems are trusted by over 7,000 healthcare facilities in more than 50 countries across five continents.

With over 1,500 employees worldwide and 2022 sales revenue reaching USD 1.5 billion, EasyDiagnosis continues to expand its technological capabilities and market influence. Its strong R&D commitment has earned multiple national recognitions, including the title of National Enterprise Technology Center (2022) and the Advanced Group Award for contributions during the COVID-19 pandemic. The company’s COVID-19 Nucleic Acid Detection Kit received CE certification in 2020, demonstrating its role in global health resilience.

Guided by the vision of “Leading real-time, accurate and smart diagnosis technology”, EasyDiagnosis upholds core values of customer focus, continuous improvement, and adaptability. The company maintains an innovative culture that emphasizes excellence, learning, and social responsibility, ensuring the delivery of reliable, high-quality diagnostic products that promote global wellbeing.

Wuhan Easy Diagnostics Biomedicine Co., Ltd

Wuhan Easy Diagnostics Biomedicine Co., Ltd